Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Qk6vn86e3t
2. 88048-09-3
3. Unii-qk6vn86e3t
4. Chembl499185
5. .beta.-d-galactopyranoside, (3.beta.,5.alpha.,22.alpha.,25r)-26-(.beta.-d-glucopyranosyloxy)-22-hydroxyfurostan-3-yl O-.beta.-d-glucopyranosyl-(1->2)-o-(.beta.-d-xylopyranosyl-(1->3))-o-.beta.-d-glucopyranosyl-(1->4)-
6. Beta-d-galactopyranoside, (3beta,5alpha,22alpha,25r)-26-(beta-d-glucopyranosyloxy)-22-hydroxyfurostan-3-yl O-beta-d-glucopyranosyl-(1->2)-o-(beta-d-xylopyranosyl-(1->3))-o-beta-d-glucopyranosyl-(1->4)-
Molecular Weight | 1215.3 g/mol |
---|---|
Molecular Formula | C56H94O28 |
XLogP3 | -3 |
Hydrogen Bond Donor Count | 17 |
Hydrogen Bond Acceptor Count | 28 |
Rotatable Bond Count | 18 |
Exact Mass | 1214.59316234 g/mol |
Monoisotopic Mass | 1214.59316234 g/mol |
Topological Polar Surface Area | 445 Ų |
Heavy Atom Count | 84 |
Formal Charge | 0 |
Complexity | 2140 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 36 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
Present study attests to previous report that Uttroside-B is pharmacologically safe up to five times IC50 dose in acute and sub-chronic toxicity models, while even IC50 dose of sorafenib is toxic to immunocompromised mice, and elevated doses of sorafenib adverse effects.
Lead Product(s): Uttroside B
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Oklahoma Medical Research Foundation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Lead Product(s) : Uttroside B
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Oklahoma Medical Research Foundation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Present study attests to previous report that Uttroside-B is pharmacologically safe up to five times IC50 dose in acute and sub-chronic toxicity models, while even IC50 dose of sorafenib is toxic to immunocompromised mice, and elevated doses of sorafenib...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 26, 2022
Details:
In the initial Scientific Reports study, researchers showed that in animal models, Uttroside-B was ten times more cytotoxic to the HepG2 liver cancer cell line than sorafenib, the only drug approved by the FDA for liver cancer approved at the time.
Lead Product(s): Uttroside B
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
Lead Product(s) : Uttroside B
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In the initial Scientific Reports study, researchers showed that in animal models, Uttroside-B was ten times more cytotoxic to the HepG2 liver cancer cell line than sorafenib, the only drug approved by the FDA for liver cancer approved at the time.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 16, 2022
Details:
The patent titled “Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma” is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC).
Lead Product(s): Uttroside B
Therapeutic Area: Oncology Brand Name: Uttroside-B
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Lead Product(s) : Uttroside B
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Q BioMed's Uttroside-B Receives Additional Patent Coverage in Canada and Japan
Details : The patent titled “Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma” is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC).
Brand Name : Uttroside-B
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 26, 2021
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?